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Summary
Mucolipidosis type IV (MLIV) is a lysosomal storage
disorder characterized by severe neurologic and oph-
thalmologic abnormalities. It is a rare autosomal reces-
sive disease, and the majority of patients diagnosed, to
date, are of Ashkenazi Jewish descent. We have mapped
the MLIV gene to chromosome 19p13.2-13.3 by linkage
analysis with 15 markers in 13 families. A maximum
LOD score of 5.51 with no recombinants was observed
with marker D19S873. Several markers in the linked
interval also displayed significant linkage disequilibrium
with the disorder. We constructed haplotypes in 26 Ash-
kenazi Jewish families and demonstrate the existence of
two founder chromosomes in this population. The lo-
calization of MLIV to chromosome 19 will permit ge-
netic prenatal diagnosis in affected families and will aid
in the isolation of the disease gene.
Introduction
Mucolipidosis (ML) type IV (MLIV; MIM 252650) be-
longs to a group of inherited metabolic diseases known
as the lysosomal storage disorders. It was first described
in 1974 as a new variant of the mucolipidoses and was
characterized by corneal clouding and abnormal sys-
temic storage bodies (Berman et al. 1974). The absence
of mucopolysaccharide excretion and the lack of iden-
tifiable lysosomal-enzyme changes distinguish it from the
mucopolysaccharidoses and from the other mucolipi-
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doses (ML type I, type II [I-cell disease], and type III),
respectively (Crandall et al. 1982).MLIV is a progressive
neurologic disease that usually presents during the first
year of life, with mental retardation, corneal opacities,
and delayed motor milestones (Amir et al. 1987). De-
finitive diagnosis of MLIV is made either by electron-
microscopic demonstration of inclusions in the lyso-
somes of different cell types in skin or by conjunctival
biopsies. Interestingly, patients with MLIV do not show
mucopolysaccharide excretion, skeletal changes, or
organomegaly, as do patients with other mucolipidoses.
To date, 180 patients with MLIV have been reported,
the majority of whom are of Ashkenazi Jewish descent
(Schiffman et al. 1998).
The storage materials in MLIV are heterogeneous,
having been identified by Bargal and Bach (1997) as
sphingolipids, phospholipids, and acid mucopolysaccha-
rides, and accumulate in the lysosomes in cells from
every tissue and organ of patients with MLIV (Chen et
al. 1998). Lipid-storage disorders typically are a result
of defective lysosomal hydrolases or activator proteins,
but extensive studies have shown that the lysosomal hy-
drolases involved in the catabolism of the storedmaterial
in MLIV have normal activity (Bach et al. 1999) and
that the storage products are normally catabolized and
discharged. Consequently, MLIV may be a result of ab-
normal transport of lipids to the lysosomes rather than
of abnormal catabolism. Experiments done in cultured
fibroblasts suggest that phospholipids and gangliosides
accumulate in MLIV as the result of a defect in the
process of endocytosis of membranous components. The
defect appears to lead to excessive transport of these
macromolecules into the lysosomes, consistent with the
heterogeneity of the stored materials in MLIV (Bargal
and Bach 1997). Examination of the movement of a lipid
analogue along the lysosomal pathway has implicated a
defect that affects the late steps in the endocytic pathway
in MLIV cells (Chen et al. 1998). A defect in the sorting
and transport pathway, rather than a degradation defect,
might explain the absence of a massive buildup of ma-
terial and the resulting organomegaly seen in other ly-
sosomal storage diseases. Recent studies done in patients
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with MLIV have shown that they are also constitutively
achlorhydric and have partially activated parietal cells.
This finding suggests that the defective protein in MLIV
probably also plays a role in parietal cell activation and
is critical to a specific type of cellular vacuolar trafficking
between the cytoplasm and the apical membrane domain
(Schiffman et al. 1998).
Since the majority of the lysosomal storage disorders
are due to defects in the catabolism of specific storage
products, it is likely that the function of the MLIV gene
will be unique in its disease-causing mechanism. The
purpose of this study is to determine the chromosomal
localization of the MLIV gene by a genomewide search
for linkage. Using 13 Ashkenazi Jewish families, we
mapped the MLIV gene to chromosome 19p13.2-13.3
and identified two founder haplotypes in the population.
The localization of the MLIV gene will permit identifi-
cation of the defective gene, which will eventually shed
light on the exact nature of the transport defect along




We collected 26 Ashkenazi Jewish families withMLIV
through collaboration with the Mucolipidosis IV Foun-
dation. Approval from the institutional review boards
at Massachusetts General Hospital, Harvard Medical
School, the National Institute of Neurological Disorders
and Stroke, and Hadassah University Hospital was ob-
tained prior to the collection of samples. For families
included in this study, MLIV was diagnosed according
to standard criteria. Patients from 16 families were seen
by R.S., and patients from 6 families were seen by G.B.
Patients from the other four families were not examined
directly by physicians involved in this study; however,
their diagnosis was uncomplicated and was made by use
of standard criteria. Four of the families had two ormore
affected members, and nine families had one or more
unaffected sibling, making them useful for linkage anal-
ysis (fig. 1). The remaining 13 families, which were com-
posed of a single affected child, parents, and, in some
cases, grandparents, were used only for haplotype anal-
ysis. In total, we studied 52 disease chromosomes, 54
non-MLIV chromosomes (obtained from heterozygote
carriers), and 17 control chromosomes (obtained from
unaffected individuals married into the MLIV families).
DNA Analysis
Genomic DNA was prepared either from lymphoblast
cell lines (Anderson and Gusella 1984) with the SDS-
proteinase K method followed by phenol extraction or
directly from blood with the Nucleon II kit (Scotlab).
PCR was performed in a total volume of 15 mL with
∼100 ng genomic DNA; 20 pmol each primer; 0.5 U
Taq polymerase; 1.5 mM MgCl2; 50 mM KCl; 200 mM
dATP, dCTP, and dTTP; 20 mM dGTP; and 0.1 uCi
a[32P]-dGTP. PCR was carried out in a PTC-100 thermal
cycler (MJ Research) with the following cycle: initial
denaturation at 94C for 2 min, followed by 30 cycles
of 94C for 20 s, 53C–60C for 20 s, and 72C for 20
s. The annealing temperature was optimized for each set
of primers. PCR products were electrophoresed on a 6%
polyacrylamide gel (90W for 2–3 h at constant power),
and autoradiography was performed by exposure of the
gels to XAR film (Kodak) for 3–4 h.
Two-Tiered Genome Scan
During the initial phase of family collection, we per-
formed a complete genome scan in five individuals from
family 1 (fig. 1) by using the Cooperative Human Link-
age Center Human Screening Set/Weber (v. 8; Research
Genetics). This screening set consists of 366 markers
with a mean spacing of 10 cM and an average hetero-
zygosity of .76. We genotyped the parents, the two af-
fected children, and one unaffected child. By evaluating
marker-sharing between the siblings, we prioritized the
markers to be genotyped in the primary linkage family
set, which consisted of families 1–3 and 6. On the basis
of the results from our initial scan, we genotyped families
1–3 and 6 for 117 markers. The additional 22 families
used in our study were genotyped only for the chro-
mosome 19 markers, after the discovery of linkage.
Statistical Analysis
To determine the power of our families to detect link-
age, we performed simulation analysis using version 2.6
of the SLINK program (Ott 1989; Weeks et al. 1990).
Five hundred replicates were simulated under a recessive
disease model with complete penetrance, with use of a
disease-gene frequency of .001. Two-point LOD scores
between the disease and individual markers were cal-
culated with the MLINK program of the FASTLINK
3.0P software package (Cottingham et al. 1993; Schaffer
et al. 1994; Schaffer 1996), a faster version of the orig-
inal LINKAGE package (Lathrop and Lalouel 1984; La-
throp et al. 1984, 1986). Haplotypes were constructed
by visual inspection of the linked markers.
Results
Genome Scan
SLINK analysis of our primary linkage family set
(families 1–3 and 6; fig. 1) yielded a maximum LOD
score of 4.38 and an average LOD score of 2.98 at
recombination fraction , indicating power to de-(v) = 0
tect linkage in these four families. The initial genome
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Figure 1 MLIV linkage families. An asterisk (*) indicates individuals not sampled.
scan was done in the parents, two affected children, and
one unaffected child from family 1.We evaluatedmarker
sharing between siblings, which resulted in the following
prioritization scheme for the genotyping of the primary
linkage family set: 14 markers were homozygous, shared
in the affected sibs and different in the unaffected sib;
64 markers were heterozygous, shared in the affected
sibs and different in the unaffected sib; and 39 markers
were uninformative in the family. This reduced to 117
the number of markers that were genotyped in families
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Table 1
Pairwise LOD Scores of Chromosome 19 Markers With the 13




RECOMBINATION FRACTION AT v =
.00 .01 .05 .1 .2 .3 .4
D19S1034 20.75  .21 .78 .84 .60 .30 .09
D19S869 22.96 3.47 3.41 3.09 2.65 1.75 .91 .26
INSR 25.17 .98 .99 .98 .89 .60 .29 .08
D19S592 )a 4.18 4.03 3.45 2.75 1.52 .63 .14
D19S406 25.17 2.37 2.31 2.07 1.76 1.15 .60 .17
D19S873 25.17 5.51 5.34 4.66 3.83 2.29 1.05 .27
D19S901 25.17 4.98 4.84 4.25 3.53 2.17 1.03 .27
D19S905 25.17 2.22 2.14 1.84 1.49 .90 .44 .12
D19S76 25.17 2.26 2.21 1.98 1.69 1.12 .59 .17
D19S912 26.37 4.55 4.43 3.93 3.30 2.06 .99 .26
D19S884 26.37  3.73 3.82 3.35 2.15 1.04 .27
D19S922 26.37  2.05 2.25 1.95 1.19 .54 .13
D19S916 31.29  2.61 2.84 2.55 1.71 .87 .24
D19S586 32.94 3.05 2.94 2.49 1.96 1.05 .43 .10
D19S906 36.22  2.08 .31 .19 .34 .21 .06
a Marker location determined on the basis of Lawrence Livermore
National Laboratory physical map of chromosome 19p.
Table 2
Haplotypes Associated with MLIV
MARKER
HAPLOTYPE D19S869 INSR D19S592 D19S406 D19S873 D19S901 D19S905 D19S76 D19S912 D19S884 D19S922 NUMBER
Major 283 3 4 207 120 152 216 3 175 230 236 39a
Minor 275 3 5 211 126 161 234 4 179 230 240 11a
Odd 1 275 2 5 211 112 157 234 4 175 236 244 1
Odd 2 277 3 4 211 114 159 218 4 175 234 244 1
a See figure 2 for details.
1–3 and 6. This is a 69% reduction in the total number
of markers, which represents a significant time and cost
savings.
Of the 117 markers genotyped in the primary family
set, four markers yielded LOD scores 12.0 at :v = 0
GATA30E06 (chromosome 2), ; D3S1265,LOD = 2.28
; D12S1300, ; and D19S586,LOD = 2.5 LOD = 2.28
. All of these regions were followed up byLOD = 2.15
genotyping the flanking markers in the screening set and,
if necessary, by the addition of closely spaced markers.
The addition of marker D19S873 gave a LOD score of
4.38 and, therefore, demonstrated significant linkage to
chromosome 19. We then saturated this region by ge-
notyping 15 closely spaced markers that map to the
19p13.2-13.3 interval in the 13 families shown in figure
1. The genetic location of the markers and the LOD
scores obtained from our analysis are given in table 1.
Recombinants in our families place the MLIV gene
within a 5.62-cM interval, between markers D19S1034
and D19S884.
Disequilibrium and Haplotype Analysis
We observed significant linkage disequilibrium with
12 of the 15 markers genotyped across this region:
D19S1034, ; D19S869, D19S592, D19S406,P ! .002
D19S873, D19S901, D19S905, D19S76, D19S912,
and D19S884, ; and INSR and D19S922,P ! .0001
. We therefore undertook haplotype analysisP ! .0002
of MLIV in an attempt to define the founder haplo-
types, refine the candidate region on the basis of his-
torical recombinants, and estimate the number of in-
dependent mutations represented in the MLIV
population. A major founder haplotype was observed
for 39 (75%) of the 52 MLIV chromosomes exam-
ined. In addition, a second less-frequent founder hap-
lotype was observed for 11 (21%) of the 52 chromo-
somes (table 2). The two remaining chromosomes
shown in table 2 display significant allele differences
at multiple markers. In each case, these “odd” hap-
lotypes were present in patients also carrying one of
the major haplotypes. These haplotypes suggest that
there may be as many as four independent gene mu-
tations that cause MLIV in the Ashkenazi Jewish pop-
ulation. None of the 54 non-MLIV chromosomes
from heterozygote carriers, nor of the 17 control chro-
mosomes, displayed a haplotype identical to any of
the MLIV chromosomes. However, 3 of the 54 non-
MLIV chromosomes shared the same alleles as the
major MLIV haplotype and as the two “odd” MLIV
haplotypes, respectively, for the core markers
D19S406–D19S873–D19S901–D19S905–D19S76.
The two frequent founder haplotypes are recognizable
across the interval from D19S869–D19S922, esti-
mated to be ∼3.41 cM. There is no genetic evidence
distinguishing the order of the markers INSR,
D19S406, D19S873, D19S901, D19S905, and
D19S76 within this interval. Marker D19S592 has
been localized physically to this region, but it is not
on any genet i c map. However, the order of
INSR–D19S592–D19S406–D19S76 is supported by
the Lawrence Livermore National Laboratory physi-
cal map of chromosome 19 (Lawrence Livermore Na-
tional Library Human Genome Center). The chro-
mosomes that support potent ia l ances t ra l
recombinants within the founder haplotypes are de-
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Figure 2 Extended haplotype analysis of 52 MLIV chromosomes with 11 markers. The major haplotype is shown in row 1 (marked with
an asterisk [*]), and the minor haplotype is shown in row 17 (marked with asterisk [*]). The other haplotypes, which have probably arisen
from ancestral recombination events, are depicted with the identical MLIV core markers outlined.
picted in figure 2. Examination of the potential an-
cestral recombinants in the founder haplotypes sup-
por t s the fo l lowing order of the markers :
INSR–D19S592–D19S406–[D19S873, D19S901,
D19S905, D19S76]–D19S912–D19S884–D19S922
and suggests that the MLIV gene maps between
D19S406 and D19S912, estimated at ∼1.2 cM. Figure
2 shows that, on the proximal side of the map, we
observe one ancestral recombinant with D19S406,
one additional recombinant with D19S592, one ad-
ditional recombinant with INSR, and one additional
recombinant with D19S869. With the distal markers,
we see 10 ancestral recombinants with D19S912, four
additional recombinants with D19S884, and one ad-
ditional recombinant with D19S922. It is important
to point out, however, that, until the exact physical
order of the markers in this region is determined, the
extent of the candidate interval for the MLIV gene
remains uncertain.
Discussion
MLIV is a unique member of a family of lysosomal
storage disorders. It is a devastating disease that causes
motor and mental retardation and severe ophthalmo-
logic abnormalities that usually lead to blindness. The
majority of patients diagnosed to date are of Ashkenazi
Jewish descent. This study provides strong evidence for
localization of the gene causing MLIV to the chromo-
some 19p13.2-13.3 region. The definition of closely
linked, highly informative markers flanking the disease
gene provides the basis for prenatal diagnosis and carrier
detection in MLIV families. Presently, prenatal diagnosis
is made by electron microscopy of amniocytes, a tech-
nique that requires a high degree of skill and expertise
in the diagnosis of MLIV. The finding of genetic linkage
will allow the prenatal test to become more widely
available.
The assignment of the MLIV gene to 19p13.2-13.3
also opens an avenue to isolating the disease gene by
positional cloning. Haplotype analysis suggests that
there are four different haplotypes that span the MLIV
region, and, therefore, potentially four independent mu-
tations. However, until the exact physical order of these
markers is determined and new markers are isolated in
the region, it is difficult to say with certainty that these
four haplotypes are completely independent. This region
of chromosome 19 is extremely gene rich; in fact, there
are 118 other disorders that have been mapped to
19p13. A scan of the public databases also shows that
1100 known genes have been mapped to the 19p13.2-
13.3 region. Although some of these can be excluded as
candidates on the basis of their fine mapping, the pu-
tative functions of the others does not reveal any that
are likely candidates for MLIV. The human transcript
map at the GeneMap’98 website (National Center for
Biotechnology Information) maps 13 genes and eight
expressed sequence tags to the interval between
D19S216 andD19S912,which would include theMLIV
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candidate region. None of the known genes are likely
candidates, since previous studies suggest that the MLIV
gene plays a role in the late-endocytic pathway and in
the final stages of parietal cell activation. Although no
obvious candidate gene for MLIV maps to this region,
the results of this study suggest that it will be possible
to narrow the candidate-gene interval by use of linkage
disequilibrium. Evaluation of the physical map of the
region will determine which of the known genes map to
the precise candidate interval and will also permit the
identification of new MLIV candidate genes.
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